Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Compounding pharmacies in Nevada

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The Nevada State Board of Pharmacy regulates compounding pharmacies in Nevada. Compounded GLP-1 limited. How to check a pharmacy's license, plus listings with their verification status.

Nevada at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Compounding pharmacies serving Nevada

No verified compounding pharmacies serving Nevada are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Nevada

The Nevada State Board of Pharmacy licenses pharmacists, pharmacies, and out-of-state pharmacies under NRS chapter 639 and adopts rules in NAC chapter 639. NRS 639.2328 provides that every pharmacy located outside Nevada that dispenses prescriptions to patients located in Nevada must be licensed by the Board, and to be licensed it must hold a pharmacy license in its home state, comply with applicable federal law, and name a responsible pharmacist. The Board's compounding rules are in NAC 639.661 to 639.690 (compounding and dispensing drug products): NAC 639.670 adopts the 2023 United States Pharmacopeia and National Formulary by reference, and NAC 639.67053 requires every pharmacist and technician who compounds sterile products to comply with USP chapter 797. Nevada has no state bulks list; peptide eligibility follows the federal 503A framework. [1] [4] [5] [6] [8]

Compounded GLP-1 access in Nevada

Nevada's telehealth definition includes asynchronous store-and-forward, and NRS 629.515 lets a Nevada-licensed provider establish a relationship by telehealth when clinically appropriate and within the standard of care; the statute does not say whether a questionnaire alone is enough. The dispensing pharmacy must be licensed by the Nevada State Board of Pharmacy. [1] [2] [11]

Research use only sellers in Nevada

Nevada's food and drug law (NRS chapter 585) prohibits selling adulterated or misbranded drugs, and NRS chapter 639 restricts dispensing of prescription drugs to licensed pharmacies and practitioners. [3] [7] [12]

Nevada notes on specific peptides

  • Semaglutide: Available branded by prescription, including from a Nevada-licensed telehealth prescriber using synchronous or asynchronous telehealth under NRS 629.515. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025. [2] [11]

How to check a compounding pharmacy in Nevada

  1. Search the Nevada State Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Nevada requires before it ships to you. [1] [4] [5] [6] [8]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Nevada. [3] [7] [12]

Common questions in Nevada

Can an out-of-state pharmacy ship compounded peptides to me in Nevada?

Only if it is licensed by the Nevada State Board of Pharmacy. Search the Board's license verification before ordering. [1] [4]

Can a Nevada pharmacy compound BPC-157?

Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Nevada has no state bulks list; peptide eligibility follows the federal 503A framework. [8] [9] [10] [13] [14]

All peptide legal questions for Nevada

Sources

  1. [1]Nevada State Board of Pharmacy
  2. [2]NRS 629.515, Telehealth: license required; establishment of relationship with patient
  3. [3]NRS chapter 639, Pharmacy
  4. [4]NRS 639.2328, Pharmacy located outside Nevada that dispenses prescriptions to patients located in Nevada: licensing
  5. [5]NAC 639.67053, Compounding standards (sterile compounded drug products, USP chapter 797)
  6. [6]NAC chapter 639, Pharmacy
  7. [7]NRS chapter 585, Food, drugs and cosmetics
  8. [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  9. [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  10. [10]FDA: Pharmacy Compounding Advisory CommitteeFDA